secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001193125-25-256378
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA places clinical hold on NTLA's Phase 3 nex-z trials after Grade 4 liver event
--------------------------------------------------------------------------------

- FDA verbally informed Intellia of clinical hold on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z (nexiguran ziclumeran).
- Hold follows Grade 4 liver transaminases and increased total bilirubin in a MAGNITUDE patient dosed with nex-z.
- Company had temporarily paused dosing/screening on Oct 27 per protocol-defined pausing criteria.
- FDA will issue a formal Clinical Hold Letter within 30 days; Intellia plans to work with FDA to resolve.
- NTLA (Nasdaq) stock expected to react to this regulatory setback.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525256378/0001193125-25-256378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312525256378/d98865d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-256378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer